Assoc. Prof. Dr. Seher Nazlı Kazaz

1997–2005 – Karadeniz Technical University (KTU), Medical Education

2007–2012 – KTU Faculty of Medicine, Department of Internal Medicine — Internal Medicine Specialization

2013–2017 – Dokuz Eylul University (DEU) Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology — Subspecialty Training

04.2007–09.2007 — Physician — Republic of Turkey Ministry of Health, Mus Bulanik Elmakaya Health Center, Mus

2007–2012 — Research Assistant (Internal Medicine) — KTU Faculty of Medicine, Department of Internal Medicine, Trabzon

2013 — Internal Medicine Specialist — Republic of Turkey Ministry of Health, Agri State Hospital, Internal Medicine Clinic, Agri

2013–2017 — Research Assistant (Medical Oncology) — DEU Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Izmir

2018–2019 — Medical Oncology Specialist — Republic of Turkey Ministry of Health, Kanuni Training and Research Hospital, Medical Oncology Clinic, Trabzon

2019–Present — Assistant Professor — KTU Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Trabzon

1. Trabzon Medical Chamber (since 2007)

2. Turkish Society of Medical Oncology (since 2014)

3. Society of Oncology and Immunotherapy (since 2017)

A1. Ulusoy S, Ozkan G, Sonmez M, Mungan S, Kaynar K, Cansiz M, Kazaz N. Absence of hypoalbuminemia despite nephrotic proteinuria in focal segmental glomerulosclerosis secondary to polycythemia vera. Internal Medicine, 2010;49(22):2477–2480. DOI:10.2169/internalmedicine.49.4087

A2. Ulusoy S, Ozkan G, Bektaş D, Kaynar K, Cansız M, Kazaz N. Ramsay Hunt syndrome in renal transplantation recipient: a case report. Transplantation Proceedings, 2010;42(5):1986–1988. DOI:10.1016/j.transproceed.2010.02.078

A3. Ozkan G, Ulusoy S, Kaynar K, Oztuna F, Cansiz M, Kazaz N. Swine H1N1 infection in a renal transplant recipient. Exp Clin Transplant, 2010;8(4):318–320. PMID:21143099

A4. Sonmez M, Kazaz N, Yucel B, Topbas M, Ucar F. C950T and C1181G osteoprotegerin gene polymorphisms… Hematology, 2014;19(4):213–216. DOI:10.1179/1607845413Y.0000000114

A5. Salman T, Kazaz SN, … Prognostic value of the pretreatment NLR and PLR… Chemotherapy, 2016;61(6):281–286. DOI:10.1159/000445045

A6. Atag E, Kazaz SN, … EBV-associated lymphoepithelioma-like carcinoma… J Clin Exp Oncol, 2016;5:6. DOI:10.4172/2324-9110.1000171

A7. Kurt S, Ulukus C, Kazaz SN, Astarcıoğlu I. Bilateral ovarian metastasis of a Klatskin tumor… Turk J Obstet Gynecol, 2016;13:215–217. DOI:10.4274/tjod.40222

A8. Kazaz SN, Oztop I. Treatment After Crizotinib Resistance in ALK+ NSCLC. UHOD, 2017;27(1). DOI:10.4999/uhod.171786

A9. Kazaz SN, Oztop I. Treatment After First-Generation EGFR TKI Resistance in NSCLC. Turkish Thoracic Journal, 2017;18:66–71. DOI:10.5152/TurkThoracJ.2017.16042

A10. Kazaz SN, Oztop I. Immune Checkpoint Inhibitors in Advanced NSCLC. Turkish Thoracic Journal, 2017;18:101–107. DOI:10.5152/TurkThoracJ.2017.17006

A11. Buyruk AM, Kazaz SN, … NLR, PLR, MPV as biomarkers in early colorectal adenocarcinoma. UHOD, 2017;27(4):220–228. DOI:10.4999/uhod.171711

A12. Atag E, Semiz HS, Kazaz SN, … Response to cabazitaxel beyond 20 cycles… Urology Journal, 2017;14(1):2985–2988. DOI:10.22037/uj.v14i1.3697

A13. Eren H, Aydın HR, … Seher Nazli Kazaz, … Whortleberry protects kidney… 2018;40(1):466–474.

A14. Yıldırım S, Kazaz SN, … Information sources of cancer patients’ relatives. J Cancer Educ, 2019;34:913–919.

A15. Atag E, Mutlay F, … Kazaz SN, … Depressive symptoms in elderly cancer patients… 2018;18(5):365–370.

A16. İlke Onur Kazaz, … Seher Nazlı Kazaz, … Bladder metastasis of gastric signet-ring cell carcinoma. Urol Case Rep, 2019;22:62–62.

A17. Ilke Onur Kazaz, … Seher Nazli Kazaz, … Primary renal angiosarcoma… Indian J Pathol Microbiol, 2020;63(5):44–46.

A18. Semiz HS, Kazaz SN, … Prognostic significance of hematological parameters in early melanoma. UHOD, 2020;30(2):103–109.

A19. İlke Onur Kazaz, … Seher Nazlı Kazaz, … Tadalafil and telmisartan in bleomycin-induced pulmonary fibrosis (rat). J Surg Med, 2020;4(8):689–692.

A20. Fidan E, Yildirim A, Kazaz N, … ALBI score and survival in pancreatic cancer. JPMA, 2022;72(7):1340–1344. doi:10.47391/JPMA.2413

A21. Kazaz SN, Yıldırım A. COVID-19 bilgi, tutum ve davranışları (kanser hastaları). Ann Clin Anal Med, 2022;13(4):389–393.

A22. Aynacı Ö, Serdar L, … Seher KAZAZ, … Radiotherapy during COVID-19: Northeast Turkey 1-year results. Turk J Oncol, 2022;37(2):200–207. doi:10.5505/tjo.2022.3463

A23. Ş. Dişli, E. Fidan, A. Özdöver, Nazlı Kazaz, F. Özdemir. Complementary/alternative treatment use in breast cancer… Ind J Med Paediatr Oncol, 2022;43:270–277.

A24. E. Fidan, S. Fidan, E. Merev, N. Kazaz. ALBI grade and survival in HCC treated with sorafenib. Niger J Clin Pract, 2022;25(2):173–177.

B1. Textbook of Gastrointestinal Oncology — “Symptom Management…”, Yavuzsen T, Kazaz N, vd. (2019)

B2. Radyonüklit Tedavi — “Tiroid Kanserinde Sistemik Tedaviler ve Yan Etkileri”, Seher Nazlı Kazaz, İlhan Öztop (2019)

B3. Radyonüklit Tedavi — “Nöroendokrin Tümörlerde Sistemik Tedaviler…”, Seher Nazlı Kazaz, İlhan Öztop (2019)

B4. Türkiye Klinikleri Özel Sayı—Jinekolojik Kanserler — “Serviks Kanserinde Sistemik Tedavi” (2019)

B5. Türkiye Klinikleri—Tıbbi Onkoloji / Akciğer — “Akciğer Kanserinde Gelecek” (2020)

B6. Türkiye Klinikleri—Radyasyon Onkolojisi — “Rektum Kanserinde Adjuvan Tedavi” (2020)

B7. Geriatrik Onkoloji — “Geriatrik Onkolojide Ölçekler”

B8. Geriatrik Onkoloji — “Geriatrik Akciğer Kanserinde Tirozin Kinaz İnhibitörleri”

B9. Türkiye Klinikleri—KBB—Özel Konular — “Oral Kavite Kanserlerinde Kemoterapi”

B10. TTOD—Meme Kanserleri — “HR+ HER2- Meme Kanserinde Takip ve Prognoz”

B11. Radionuclide Therapy (Springer, 2022) — “Systemic Treatments in Thyroid Cancer”, İlhan Öztop, Seher Nazli Kazaz

B12. Radionuclide Therapy (Springer, 2022) — “Systemic Treatments in Neuroendocrine Tumors”, İlhan Öztop, Seher Nazli Kazaz

C1. Keser M, Kazaz SN, Karaoğlu A. Medüller Tiroid Kanseri. Türkiye Klinikleri J Med Oncol—Special Topics, 2017;10(1):91–96.

C2. Semiz HS, Kazaz N, Karaoğlu A. Akciğer Kanserinde Adjuvan/Neoadjuvan Sistemik Tedavi. Türkiye Klinikleri J Thor Surg—Special Topics, 2017;8(1):264–271.

C3. Celal Alandaş, Seher Nazlı Kazaz, Bengü Çobanoğlu. Adenoid Kistik Karsinom; Tek Merkez 15 Yıl. EJMI, 2021;5(4):491–495.

D1. Sönmez M, Kazaz N, … OPG gene polymorphisms and myeloma bone disease. ASH 2013, New Orleans — Blood 2013;122:3128

D2–D8. Case reports and presentations on gastrointestinal and colon cancers in collaboration with DEU and the Izmir Oncology Group (2014, Istanbul)

E1–E3. Nephrology and transplantation presentations (2010)

E4. Early leukocyte decline after chemotherapy and prognosis in acute myeloid leukemia (2012)

E5–E25. Presentations on geriatric oncology, rare tumors, gastrointestinal and colon cancers (2014–2015)

E26–E33. Presentations on breast cancer, melanoma, lung cancer and immunotherapy (2015–2016)

E34–E38. Presentations on immuno-oncology, rare lung tumors and case series (2016–2021)

2016–2022: Numerous conferences including “Perspectives in Oncology”, “Geriatric Oncology”, “Uro-oncology”, TTOK, TAKD, etc., as speaker / session chair (topics: immunotherapy side-effect management, targeted therapies, mCRC sequencing, NSCLC biomarkers, perioperative treatments, etc.)

2004 – Rational Drug Selection and Use (KTU)

2009 – Kidney Transplant Pathology (KTU)

2014–2017 – TTOD Update Courses (Head-Neck, CNS, Sarcomas, Basic Oncology)

2015 – “Diagnosis–Treatment–Management in Metastatic Colorectal Cancer”, Oldenburg/Germany

2019 – KTU Clinical Research Center Good Clinical Practice (GCP) Certificate

2021 – “Advances in Hormone Therapy in Prostate Cancer” (Speaker)

Between 2009–2022: attended National Cancer Congresses, ASCO, ESMO, EMUC, St. Gallen, EIKCS, national immunotherapy/oncology congresses, and regional symposiums (on-site and e-congress)

Investigator / Co-Investigator: PERTAIN, PERUSE, ASQoP, ExteNET, D-CARE, Javelin Lung 200, KEYNOTE-905, KEYNOTE-866

Principal Investigator (PI): tislelizumab plus chemotherapy (NCT03777657), KEYNOTE-992 (NCT04241185), BLC 2002 NORSE (NCT03473743), CBYL719K12301

Lung cancer

Breast cancer

Gynaecological cancers

Urogenital cancers

Colorectal cancer

Chemotherapy

Immunotherapy

Molecularly targeted treatments

Multidisciplinary treatment approaches